SYNERGY PHARMACEUTICALS LLC
SYNERGY PHARMACEUTICALS LLC (SGYP): 2 pipeline candidates · ~2 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.9 months
D/E -1.86 · 0% dilution
Lead: Approved
2 candidates
N/A
N/A
A transparent, data-derived signal for SYNERGY PHARMACEUTICALS LLCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$45.6M
Quarterly Burn
$89.1M
Runway
1.9 mo
Revenue
$11.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| dolcanatide | Preclinical |
| trulance | Approved |
Frequently asked questions
How many drug candidates are in SYNERGY PHARMACEUTICALS LLC's pipeline?
SYNERGY PHARMACEUTICALS LLC (SGYP) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SYNERGY PHARMACEUTICALS LLC's lead drug candidate?
SYNERGY PHARMACEUTICALS LLC's most advanced tracked candidate is dolcanatide (Preclinical) for GI diseases and disorders.
What is SYNERGY PHARMACEUTICALS LLC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SYNERGY PHARMACEUTICALS LLC has approximately 1.9 months of cash runway.
Get the full picture on SYNERGY PHARMACEUTICALS LLC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.